Retrospective study of Velphoro in Hyperphosphataemia published in Kidney Medicine journal.- Fresenius Medical

A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target serum phosphorous levels of less than or equal to 5.5 mg/dL compared to those patients who switched from Velphoro to another phosphate binder. The analysis examined 222 patients who remained on Velphoro maintenance therapy for two years, and compared those patients to a comparator group of 596 patients who discontinued the drug within 90 days and switched to other phosphate binders.

A higher percentage of patients who remained on Velphoro achieved target serum phosphorus levels with about half the number of phosphate binder pills per day. A total of 45 percent of patients using Velphoro achieved target levels with that lower pill burden compared to 31.9 percent of patients who switched to other binders with no change in pill burden.

See: “Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study.” Daniel W.Coyne et al. Kidney Medicine, Available online 26 March 2020 https://doi.org/10.1016/j.xkme.2020.01.009